Premium
Primary cutaneous CD30+ T‐cell lymphoma responsive to topical imiquimod (Aldara ® )
Author(s) -
Didona B.,
Benucci R.,
Amerio P.,
Canzona F.,
Rienzo O.,
Cavalieri R.
Publication year - 2004
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.2004.05993.x
Subject(s) - imiquimod , medicine , cd30 , dermatology , lymphoma , primary (astronomy) , immunology , physics , astronomy
Summary CD30+ anaplastic large cell lymphoma is a primary cutaneous lymphoproliferative disorder with a high rate of spontaneous regression (almost 25%). The suggested therapies are radiation, surgery and methotrexate. We describe two patients with nonregressing primary cutaneous CD30+ T‐cell lymphoma that was successfully treated with topical imiquimod 5% cream (Aldara ® , 3M) three times weekly for 6 weeks. In both cases we obtained complete clinical remission, confirmed by histology. No recurrences were observed during the following 8 months. We consider that topical application of an immune response modifier, such as imiquimod, could be a good alternative to other potentially more dangerous or aggressive treatments.